S-WoPEc
 
Scandinavian Working Papers in Economics
HomeAboutSeriesSubject/JEL codesAdvanced Search
HUI Research HUI Working Papers, HUI Research

No 7:
Deregulating the Norwegian Pharmaceuticals Market - Consequences for Costs and Availability

Niklas Rudholm ()

Abstract: The aim of this paper is to analyze the impact of the deregulation of the Norwegian pharmaceuticals market in 2001 on costs and availability of pharmaceutical products. Data has been collected from the annual reports of a sample of Norwegian pharmacies before and after the deregulation of the market. In addition, data regarding the number of pharmacies in each region in Norway has also been collected. In order to study costs, a translog function is estimated. Regressin models for the number of pharmacies in each region in Norway are also estimated. The results show that the costs of the individual pharmacies have not decreased as a consequence of the deregulation of the Norwegian pharmaceuticals market. The deregulation of the market did, however, increase the availability to pharmacy services substantially. The number of pharmacies increased from 392 in year 2000 to 524 in June 2004.

Keywords: Deregulation; pharmaceuticals; translog cost function; (follow links to similar papers)

JEL-Codes: I11; I18; L11; (follow links to similar papers)

14 pages, April 4, 2007

Download Statistics


This paper is published as:
Rudholm, Niklas, (2008), 'Deregulating the Norwegian Pharmaceuticals Market - Consequences for Costs and Availability', Health Policy, Vol. 87, pages 258-263



Questions (including download problems) about the papers in this series should be directed to Helena Nilsson ()
Report other problems with accessing this service to Sune Karlsson () or Helena Lundin ().

Programing by
Design by Joachim Ekebom

Handle: RePEc:hhs:huiwps:0007 This page was generated on 2016-03-01 16:33:09